文献速递冠心病外科瓣膜外科主动脉外科

冠状动脉旁路移植术联合PCSK9抑制剂治疗后冠状动脉瘤显著消退

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本文报道一例43岁家族性高脂血症男性患者,因巨大右冠状动脉瘤伴广泛斑块及严重狭窄导致心绞痛,行6处吻合口的冠状动脉旁路移植术,术后启用PCSK9抑制剂。术后5年影像显示冠状动脉瘤逐渐缩小,8年后进一步缩小,提示联合治疗可能促进冠状动脉瘤消退。

要点

  • 冠状动脉瘤患者行CABG后联合PCSK9抑制剂治疗,随访8年动脉瘤持续缩小。
  • PCSK9抑制剂对冠状动脉瘤的消退作用此前数据有限,本例提供罕见临床证据。
  • 需长期影像随访评估PCSK9抑制剂对冠状动脉瘤的影响。

核心结论

  • CABG联合PCSK9抑制剂治疗后,巨大右冠状动脉瘤在8年内逐渐且进一步缩小。

研究设计与样本

  • 单例病例报告:43岁男性家族性高脂血症患者,因巨大右冠状动脉瘤伴广泛斑块及严重狭窄行CABG(6处吻合口),术后启用PCSK9抑制剂。

主要发现

  • 术后5年影像显示冠状动脉瘤逐渐缩小。
  • 术后8年影像显示动脉瘤尺寸进一步缩小。

临床怎么用

  • 对合并巨大冠状动脉瘤的冠心病患者,CABG术后可考虑启用PCSK9抑制剂并长期影像随访。

局限性

  • 仅为单例病例报告,证据级别低,无法推广至所有冠状动脉瘤患者。
  • PCSK9抑制剂对冠状动脉瘤的效应数据有限,需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer clinical benefits by reducing low-density lipoprotein cholesterol levels and have emerged as valuable therapeutic agents for the management of cardiovascular diseases. Although their effectiveness in treating coronary artery plaques and abdominal aortic aneurysms has been reported, data on their effects on coronary artery aneurysms are limited. Herein, we report the case of a 43-year-old man with familial hyperlipidemia who presented with angina pectoris caused by a giant right coronary artery aneurysm accompanied by extensive plaques and severe stenosis. The patient underwent coronary artery bypass grafting at 6 anastomotic sites, and a PCSK9 inhibitor was initiated postoperatively. Five years after surgery, imaging demonstrated a gradual reduction in the size of the coronary artery aneurysm, and 8 years later, the size was further reduced. This case report illustrates the rare clinical course of a coronary artery aneurysms.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Yokoyama Y, Higashino H, Fujieda H, et al. Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 41247317. doi:10.1093/icvts/ivaf272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。